Skip to main content

  • Non-Trial SAVR Patients Have Comparable Mortality, Fewer Strokes Than Trial Patients From PARTNER 3 and Evolut Low Risk: Cross-Sectional Study

    Low-risk, trial-like patients undergoing surgical aortic valve replacement (SAVR) during the trial enrollment period have similar 30-day rates of mortality, but lower rates of stroke, compared with patients in the SAVR arm of the PARTNER 3 and Evolut Low Risk trials, a cross-sectional analysis shows. 

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details